Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus KEFLET.
CECLOR CD vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic